Activity Snapshot

Track 1: Recommendations for Medical and Pharmacy Directors
Track 2: Recommendations for Care Managers

Target Audience

This activity has been designed to meet the educational needs of medical directors, pharmacy directors, clinical pharmacists, quality directors, registered nurses, as well as network physicians affiliated with various managed care organizations.

Statement of Need/Program Overview

Managed care professionals and affiliated clinicians involved in the management of and direct care for patients at risk for thromboembolic disorders are routinely challenged with multiple sets of anticoagulation guidelines and protocols specific to their individual hospital, anticoagulation clinic, and/or third party payer settings. This can lead to unexpected barriers to care, disrupted communication between caregivers, and inconsistency in the delivery of care. Evidence-based practices and consistent guidelines for screening, preventing, diagnosing, tracking, and treating thromboembolic disorders are needed, especially for patients at higher risk, to ensure that these practices are routinely applied by health care professionals in all settings.

Managed care organizations are in an excellent position to collaborate in the management of thromboembolic disorders. Managed care professionals and all members of a patient care team need to learn how to adapt their current approach and roles as providers to implement new treatment regimens that emphasize a more convenient and patient-centered approach for anticoagulation therapy.

Educational Objectives (Track 1)
After completing this activity, the participant should be better able to:

- Apply evidence-based clinical practice guidelines for thromboprophylaxis in atrial fibrillation
- Evaluate recent advances in thromboprophylactic therapy including patient risks and benefits of emerging anticoagulants compared with standard treatments
- Provide appropriate care and counsel for patients and their families
- Provide accurate and appropriate counsel as part of the treatment team

Educational Objectives (Track 2)
After completing this activity, the participant should be better able to:

- Employ managed care strategies that incorporate existing and evolving therapies into treatment guidelines
- Personalize the managed care implementation processes to improve outcomes for patients at risk for thromboembolic events
- Provide appropriate care and counsel for patients and their families
- Provide accurate and appropriate counsel as part of the treatment team

Disclosure of Conflicts of Interest
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jeffrey D. Dunn, PharmD, MBA
Advisory board: Johnson & Johnson

James B. Groce III, PharmD
Consultant/advisory role for and receives honoraria from: Boehringer Ingelheim; Ortho-McNeil; Sanofi-aventis

Robert T. Weibert, PharmD
Receives fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speakers’ bureaus): Boehringer Ingelheim

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Steve Casebeer, MBA
No financial interest/relationships relating to the topic of this activity

The following PIM planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN, and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Discloser of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Impact Education, LLC, and Bristol-Myers Squibb do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The Annenberg Center, PIM, Impact Education, LLC, and Bristol-Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Media
Internet

Fee Information
There is no fee for this educational activity.

This activity is jointly sponsored by Impact Education, LLC (IE), and Postgraduate Institute for Medicine (PIM)

This activity is supported by an independent medical educational grant from the Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership.